Clinical trial
A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma
NCT03829254 is registered in ClinicalTrials.gov with NuCana plc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma
- Lead sponsor
- NuCana plc
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- June 17, 2019
- Completion date
- August 31, 2026
- Enrollment
- 135 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.